NCT00000980 is a Phase 1 clinical trial of Spiramycin in Cryptosporidiosis, sponsored by Rhone-Poulenc Rorer.

Who is sponsoring NCT00000980?

NCT00000980 is sponsored by Rhone-Poulenc Rorer.

What drugs are being tested in NCT00000980?

Interventions in NCT00000980: Spiramycin.

What condition does NCT00000980 study?

NCT00000980 studies Cryptosporidiosis, HIV Infections.

Is NCT00000980 still recruiting?

NCT00000980 is currently completed. Last updated 23 June 2005.

Last reviewed 2005-06-23 · How we verify

NCT00000980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea

Completed Phase 1 Last updated 23 June 2005

What this trial tests

Phase 1 trial testing Spiramycin in Cryptosporidiosis in 25 participants. Completed.

Quick facts

Lead sponsor	Rhone-Poulenc Rorer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	25
Sites	7 locations across United States

Drugs / interventions tested

Spiramycin (SPIRAMYCIN) — full drug profile →

Conditions studied

Cryptosporidiosis — all drugs for Cryptosporidiosis →
HIV Infections — all drugs for HIV Infections →

Sponsor

Rhone-Poulenc Rorer

Who can join

13 and older, any sex, with Cryptosporidiosis or HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the safety and effectiveness of intravenous spiramycin in patients with AIDS-related cryptosporidial diarrhea. Spiramycin, a macrolide antibiotic, has been studied in the United States for the treatment of cryptosporidial diarrhea. Some reports suggest that spiramycin is useful in improving the symptoms of cryptosporidial diarrhea in some patients. Results of one study, however, showed no significant difference between spiramycin and placebo (inactive medication). A later study indicated that the absorption of spiramycin is significantly decreased when food is present. Thus, the results of the trial may have been due to poor absorption of spiramycin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cryptosporidiosis

Currently open trials in the same condition.

NCT07249463 — Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00000980 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rhone-Poulenc Rorer
Last refreshed: 23 June 2005

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00000980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing